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S100B is a calcium signaling protein that is a member of the S100 protein family. An important feature of S100B and most other
S100 proteins (S100s) is that they often bind Ca2+ ions relatively weakly in the absence of a protein target; upon binding their
target proteins, Ca2+-binding then increases by as much as from 200- to 400-fold. This manuscript reviews the structural basis
and physiological signiﬁcance of increased Ca2+-binding aﬃnity in the presence of protein targets. New information regarding
redundancy among family members and the structural domains that mediate the interaction of S100B, and other S100s, with
their targets is also presented. It is the diversity among individual S100s, the protein targets that they interact with, and the Ca2+
dependency of these protein-protein interactions that allow S100s to transduce changes in [Ca
2+]intracellular levels into spatially and
temporally unique biological responses.
1.Introduction
Ca2+ ions are important second messengers in all living
cells [1]. Ca2+-binding proteins, including members of
the calmodulin/troponin/S100 superfamily, maintain the
integrity of the Ca2+ signal and transmit it in a temporally
and spatially coordinated manner [2]. S100s were discovered
in 1965 [3], and as with other EF-hand containing proteins,
S100s also transduce changes in [Ca2+]intracellular levels (i.e.,
[Ca2+]i) into cellular responses by binding Ca2+ (Table 1),
changing conformation, and then interacting with and
modulating the activity of other proteins (target proteins)
(Figure 1). The amino acid homology between the current
family members ranges from approximately 20% to 55%
[4]. Because of the extensive amino acid homology between
S100B and S100A1, the ﬁrst two family members identi-
ﬁed, early models predicted that individual members were
functionally redundant and essentially interchangeable. As
the number of family members discovered has increased
and diﬀerences in their cellular/subcellular localization,
physical properties, and target proteins have expanded,
additional models have arisen with speciﬁc S100 family
members having unique biological functions [5–12]. This
multigenic family now contains up to twenty-one members
(humans) whose phylogenetic distribution is restricted to
higher chordates. Oligomerization properties, aﬃnities for
divalentmetalions (Ca2+,Z n 2+,C u 2+),andposttranslational
modiﬁcations also contribute to diversity among S100 family
members [7, 12]. Furthermore, each cell/tissue expresses a
unique subset of family members [11, 12]. Collectively, these
ﬁndings support the view that S100s often confer cell type
speciﬁcity to Ca2+ signal transduction pathways in cells and
tissues [11–16].
The 3-dimensional structure of numerous S100 proteins
has been solved by NMR and X-ray crystallography tech-
niques in the apo-, Ca2+-bound, Zn2+-bound, drug-bound,
and target protein bound states, and with the exception of
calbindinD9K, S100s such as S100B are typically symmetric
dimers with each subunit containing two EF-hand calcium-
binding domains, although, some higher-order oligomeric2 Cardiovascular Psychiatry and Neurology
VOC ROC
Stimulus
Receptors
PLC
SOC
RYR
ER/SR
InsP3
InsP3R
Ca2+
Mitochondrion
S100’s
C
e
l
l
u
l
a
r
r
e
s
p
o
n
s
e
Targets
SMOC
Uniporter
PMCASERCA
NCX
μs
ms
s
min
hr
Ca2+ Ca2+ Ca2+ Ca2+
S100’s
Ca2+
Ca2+
Ca2+
Ca2+
Figure 1: S100s function as Ca2+-signaling proteins. S100s bind and regulate protein targets as well as other Ca2+-signaling proteins in a
Ca2+-dependent manner. S100s are distributed in a cell-speciﬁc manner to generate cell-type speciﬁc activities [1, 2, 10].
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Figure 2: The Ca2+-dependent S100-target protein interactions. In
red/blue are subunits of S100B (
dimerKD < 500pM [1, 17]) with
regions shaded (yellow) for residues that bind targets such as
p53367−388 (green), p53 (p53321−346,K D = 24 ± 10nM), or TRTK12
[10, 18].
states have also been detected and discussed [17–64]. The
ﬁrst EF-hand motif (EF1) in each subunit has fourteen
rather than twelve residues and is termed the “pseudo-EF-
hand” or “S100 EF-hand” [31, 65]. Another unique feature
of the S100-hand (EF1) is that calcium-coordination is
achieved via backbone carbonyl oxygen atoms rather than
sidechain carboxylate oxygen atoms, and it typically binds
Ca2+ rather weakly (KD > 0.5mM). The second EF-hand
(EF2) is termed the “typical EF-hand” since it has the
same number of residues as most EF-hand Ca2+-binding
proteins (i.e., twelve), and it exactly matches the consensus
EF-hand in both sequence and three-dimensional structure
[66]. As with the helix-loop-helix Ca2+ binding domains of
othermembersoftheEF-handsuperfamily(i.e.,calmodulin,
troponin C, etc.), the second EF-hand of S100B coordinates
Ca2+ via a backbone carbonyl oxygen at position 7, sidechain
oxygen atoms from Asp/Glu at positions 1, 3, and 5, and
via bidentate coordination from oxygen atoms from a Glu
sidechain at position 12 [66]. Position 9 of the coordination
scheme is occupied by a water molecule that is, in turn,
hydrogen-bonded to a Glu sidechain oxygen atom from
the pseudo-EF-hand. Another feature of S100B and several
other S100s is that several of them bind Ca2+ ions relatively
weakly, relative to [Ca2+]i, in the absence of a protein target
(KD ≥ 1μM). However, upon binding their full-length
target protein, Ca2+-binding can then increase by as much as
from 200- to 400-fold [60, 67]. This feature could allow for
cells to contain high concentrations of some S100s, such as
S100B (>1μM), without depleting [Ca2+]i levels and “short-
circuiting” Ca2+ oscillations necessary for signaling.
The large number of protein targets that S100B and
other S100 family members bind and regulate provides
yet another level of diversity/complexity to S100 signaling.
Examination of the extensive lists of S100 target proteins
providesimportantinsightsregardingS100signaling[15,68,
69]. First, S100s regulate a wide-range of cellular processes
that includes energy metabolism, cytoskeleton organiza-
tion, gene expression, and signal transduction pathways.
Second, the list of in vitro target proteins for individual
family members can be extensive, 23–25 diﬀerent proteinCardiovascular Psychiatry and Neurology 3
targets have been reported for S100B and S100A1 alone
[5, 7, 13, 15, 68, 70]. Third, some target proteins interact
with and have their activity modulated by multiple S100
family members suggesting functional redundancy among
some family members. For example, both S100A1 and
S100B interact with and activate aldolase A and aldolase
C[ 71]. In contrast, S100A1 and S100B exhibit a Ca2+-
dependent interaction with phosphoglucomtutase but this
interaction results in diﬀerential eﬀects on target protein
activity: S100A1 stimulates phosphoglucomutase activity
and S100B inhibits phosphoglucomutase activity [72]. Like
phosphoglucomutase, both S100A1 and S100B bind glyco-
gen phosphorylase a [73]. However, S100A1 inhibits and
S100B has no eﬀect on glycogen phosphorylase activity.
Interestingly, S100A4, S100A1, and S100A6 interact with
methionine aminopeptidase 2, but with diﬀerent aﬃnities
[74]. The S100A6 (calcyclin) binding protein CACYBP also
interacts with S100A1, S100A12, S100P, and S100B but
not S100A4 [75]. And several S100 proteins (i.e., S100A1,
S100A2, S100A4, S100A6, and S100B) bind to p53, p63,
p73 [29, 76–80], and aﬀect their biological functions [81–
84]. Fifth, S100 activation of some target proteins is Ca2+-
independent indicating that S100s sense changes in [Ca2+]i
levels and have important intracellular functions at both
resting and stimulated [Ca2+]i levels. Sixth, a subset of
S100s have a conserved Zn2+-binding site that contributes
to altered Ca2+-, target-, and in some cases, small molecule
bindingaﬃnityinvitro[8,20,36,40,68,85–99],whichcould
potentially aﬀect cellular functions. Seventh, the interaction
of S100 family members with other family members as
“target proteins” has been observed using yeast-two hybrid
approaches [100–104]. Finally, S100 proteins may exert
some of their eﬀects via interaction with molecules other
than proteins. For example, S100A8/S100A9 binds (poly)
unsaturated fatty acids in a Ca2+-dependent manner [105,
106] and S100A1 binds IP3 (Baron, Coburn, and Zimmer,
personal communication). New information regarding S100
family member speciﬁcity for individual target proteins and
the structural motifs that mediate these interactions are
detailed below. As discussed, the diversity among individual
S100s, the protein targets that they interact with, and
the Ca2+ dependency of these interactions are uniquely
suited to conferring cell-type speciﬁcity to Ca2+-signaling
pathways.
1.1. The S100 Calcium-Switch. Biophysical and structural
biology techniques are used to study molecular determi-
nants involved in Ca2+-dependent S100-target interactions.
A comparison of apo- and Ca2+-bound S100B (B-Ca2+)
indicates that the pseudo -EF-hand (EF1, CaKD > 350μM,
Table 1) has minor structural changes when Ca2+ binds,
whereas, the typical EF-hand (EF2, CaKD = 56 ± 9μM,
Table 1) has a large repositioning of several sidechain oxygen
ligands during Ca2+ coordination (EF-2: D61, D63, D65,
E67, D69, and E72) [23, 24, 26, 34, 78, 87, 107–109].
Much like S100A1, S100A4, and S100A5, Asp-61 and Asp-
63, in positions 1 and 3 of the typical EF-hand, must rotate
substantially to achieve a suitable Ca2+ binding orientation
in S100B (Figures 2 and 4). That helix 4 is involved in the
dimer interface explains why the entering helix 3 and not
the exiting helix 4 moves signiﬁcantly upon Ca2+ binding
[23]. The conformational change, termed the “S100 Ca2+-
switch”, is a feature unique to S100s and unlike other EF-
hand proteins (i.e., calmodulin and troponin C) in which
position 12 reorients the exiting helix upon Ca2+ binding
[23,26,43,44,110,111].Theconformationalchangeofhelix
3 involves breaking and forming hydrophobic contacts in
several S100s with unique hydrophobic and/or hydrophilic
residues becoming exposed for binding its protein target
(Figures 2–4). However, S100A10 does not conform to
other family members since it lacks a functional EF-hand
Ca2+-binding domain, so its target protein interactions are
all independent of Ca2+ [11, 112]. In several S100-target
structures, much has been learned about speciﬁc target- and
inhibitor-S100 interactions involving the “hinge (loop 2)”,
the C-terminal loop, and the hydrophobic pocket involving
helices 3/4 for several S100s (site 1), a second surface, nearby
helix 4 and the Zn2+ site in S100B (i.e., site 2) was also
discovered more recently in drug design studies aimed at
inhibiting S100B [20, 21].
However, several important aspects pertaining to the
Ca2+- and target-binding properties of S100s are not yet
answered. With S100A5 and S100Z as exceptions ( CaKD ∼
0.2μM, Table 1), dimeric S100s typically have a low aﬃnity
for binding Ca2+ in vitro ( CaKD ≥ 1μM, EF2) [10, 124,
134](Table 1), leading some to classifying this family of
proteins as “calcium-buﬀers” while others predicted that
S100s only bound Ca2+ in locations where Ca2+ ion concen-
trations were relatively high (endoplasmic reticulum and the
extracellularspace).Whilelowinvitrobindingaﬃnitieswere
ﬁrst thought to eliminate a role for S100 Ca2+-binding in
thecytosol,where[Ca2+]i typicallyoscillatesbetween0.1and
1μM[ 1, 2], we now know that for many S100s, their Ca2+-
binding aﬃnity goes up signiﬁcantly when its target protein
is bound [34, 60, 109]( Figure 3). In fact, for S100A1 and
thefull-lengthryanodinereceptor(Figure 3(c)),thecomplex
was detected at resting cytosolic [Ca2+]i (i.e., at 100nM)
even though its Ca2+-binding aﬃnity in vitro in the absence
of target is ∼300-fold higher ( CaKD = 27 ± 2μM) [60]
(Table 1). One explanation for the tightening Ca2+-binding
aﬃnity is that target binding induces a structural change
to provide a more optimal Ca2+-coordination geometry.
Such an explanation was ruled out for S100B when the X-
ray structures of Ca2+-S100B (±TRTK12) and found that
the Ca2+-coordination in both EF-hands (EF1, EF2) was
indistinguishable despite the fact that
Cakoﬀ is ∼20-fold
slower when TRTK12 is bound [34]. Thus, the mechanism
for “tightening” of Ca2+-binding with target bound cannot
be explained by structural data alone. Interestingly, B-factors
from X-ray structures (Figure 4)a n d15NN M Rr e l a x a t i o n
rate studies of S100s have given us some indication that
dynamic properties of S100 proteins are involved in the
“tightening eﬀect” (Figure 5). Thus, “induced-ﬁt” versus
“selected-ﬁt” binding models for both the binding of Ca2+
and target to S100s have been considered. The underlying
premise of the “selected-ﬁt” model is that in the absence
of target, the Ca2+-S100 complex observed in the X-ray
structure is in equilibrium with a dynamic state(s) that has4 Cardiovascular Psychiatry and Neurology
Table 1: Dissociation of Ca2+ and Mn2+ from the EF-hand calcium-binding domains in wild-type and mutant S100 proteins.
S100 protein EF1 EF2
Ca2+ binding
S100B (wt) >350μM
a,c 56 ± 9μM
b,c
S100B (E31A) >500μM
a >500μM
a
S100B (E72A) 480 ± 130μM
a >500μM
a
S100B (E31A + E72A) >2mM
a >2mM
a
S100B (+p53) — 20 ± 3μM
a
S100B (E31A, +p53) — 21 ± 7μM
a
S100B (E72A, +p53) — 18 ± 4μM
a
S100B (E31A + E72A, +p53) — >300μM
a
S100B (wt, +TRTK12) — 12 ± 7μM
c
S100A1 (wt) — 27 ± 2μM
d
S100A1 (wt, +TRTK12) — 8 ± 3μM
e
S100A2 (wt) — 470 ± 50μM
f
S100A3 (wt) — ∼4mM
g
S100A4 (wt) — ∼2.6μM
h
S100A4 (wt, +p37) — ∼0.2μM
h
S100A5 (wt) 160μM
i ∼0.2μM
i
S100A6 (wt) — ∼3.0μM
j
S100A7 (wt) — ∼1.0μM
k,l
S100A11 (wt) — ∼0.5mM
m
S100A12 (wt) — ∼50μM
n
S100A13 (wt) ∼400μM ∼8μM
o,p
S100A16 (wt) no binding 0.43mM
q
S100P (wt) ∼800μM ∼2.0μM
r
S100Z (wt) > 1mM ∼0.2μM
s
Mn2+ binding
S100B (wt) — 71 ± 12μM
a,c
S100B (wt, +p53) — 27 ± 4μM
a,c
S100B (wt, +TRTK12) — 6.0 ± 2.0μM
a,c
aThe value listed is from previously published papers [109, 113], so direct comparisons of binding constants using similar methods/conditions could be made
(+/− target, Figure 3). Several others report binding constants using diﬀerent methods and varying conditions for EF1 (200μM ≤ KD ≤ 500μM) and for EF2
(10μM ≤ KD ≤ 60μM) [58, 78, 86, 87, 114–120].
bThe dissociation rate constant for wild-type S100B was determined via stopped-ﬂow methods and is koﬀ = 60 ± 22s−1. The oﬀ-rate together with the KD
enables the calculation of a macroscopic on-rate value of kon = 1.1 × 106 M−1 s−1 that includes calcium-association plus a large conformational change. The
KD value for the mutants was also determined using competition studies of Ca2+ with the respective Tb3+-bound S100B mutant in the absence and presence
of p53 peptide. The dissociation constants together with the calcium oﬀ-rate values measured for the E31A and E72A mutants of 7.1 ± 3.7s−1 and 6.8 ±
2.0s−1,r e s p e c t i v e l y ,w e r es u ﬃcient to calculate on-rate values of 3.4 ± 2.0 × 106 M−1 s−1 and 3.7 ± 1.3 × 106 M−1 s−1 for the mutants [109, 113].
cFrom Charpentier et al. (2010) [34].
dFrom Wright et al. (2005) [61].
eFrom Wright et al. (2009) [59]. S100A1 has also been shown to bind the full-length ryanodine receptor at 100nM free Ca2+ [60, 67].
fFrom Franz et al. (1998) [89].
gFrom Fritz et al. (1998). A tenfold weaker aﬃnity was reported when puriﬁed under aerobic conditions [90, 121].
hFrom Dukhanina et al. (1998). A weaker aﬃnity was reported under diﬀerent conditions in Pedrocchi et al. (1994) when S100A4 was originally discovered
[122, 123].
iFrom Sch¨ afer et al. (2000). For a direct comparison of Ca2+ and Zn2+ binding to S100A5 to those of other S100 proteins (i.e., S100B, S100A2, S100A3,
S100A4, S1006, and S10011), under identical conditions and Methods, also see Sch¨ afer et al., (2000) [124].
jFrom Kuznicki and Filipek (1987) and Mani and Kay (1990). Kordowska et al. also measured Ca2+-binding for S100A6 under diﬀerent conditions
( CaKD ∼18μM) and found that binding to the target caldesmon (CaD) increased the aﬃnity of S100A6 for Ca2+ by approximately 6-fold [96, 125, 126].
Other measurements under higher salt and other varying conditions are also reported with weaker aﬃnities for S100A6 [68, 124].
kFrom Sch¨ afer et al. (2000) [124]. Weaker binding to Ca2+ has also been reported for this protein in other conditions [127].
lNo data is available for S100A8/A9, and S100A10 does not bind Ca2+.
mFrom Allen et al. (1996) and Sch¨ afer et al., (2000) [124, 128]. Note the aﬃnity for Ca2+ increases by 10-fold upon the addition of a target molecule as found
with other S100 proteins [128].
nFrom Dell’Angelica et al. (1994). Note that Zn2+-binding to S100A12 signiﬁcantly increases Ca2+-binding aﬃnity for this protein in the presence of Zn2+
(EF2: CaKD = 40nM, EF1: CaKD = 15μM) [129].
oFrom Ridinger et al. (2000). This protein is unique among S100 family members in that it does not bind to the hydrophobic binding dye, TNS, upon the
addition of Ca2+ [130].
pNo data is yet available for S100A14, and there is no S10015 [131].
qFrom Sturchler et al. (2006). The value in the table is for human S100A16, mouse S100A16 bound one calcium too, only weaker (CaKD = 0.75mM) [132].
rFrom Becker et al. (1992) and Gribenko et al., (1998) [92, 133]. In Gribenko et al., (1998), the eﬀects of Mg2+ binding on Ca2+ aﬃnity are also rigorously
addressed.Cardiovascular Psychiatry and Neurology 5
al o w e rC a 2+-binding aﬃnity; when target protein binds
to an Ca2+-S100 complex, the equilibrium shifts so “low
aﬃnity states” are eliminated when target binds to give
less conformational exchange and an increase in measured
Ca2+-binding (i.e., less free Ca2+, slower
Cakoﬀ, Figure 3).
Important for drug design, we found that S100B inhibitors
can mimic target binding to also cause higher aﬃnity Ca2+
binding (i.e., KD < 1μM). It is also now understood that
weak Ca2+-binding for S100s in the absence of target may
also turn out to be biologically relevant (Figure 1). Since
most target-free S100s have low aﬃnity for Ca2+, this allows
numerous stable S100s to be at high concentrations in the
cell (>1μM) without depleting [Ca2+]i levels inside the cell
and “short-circuiting” Ca2+ oscillations. Thus, several highly
stable S100s can be “poised and ready” in any given cell for
when their speciﬁc target(s) are expressed, as necessary for
them to regulate numerous functions in mammalian cells
(Figure 1)[ 109].
1.2. The S100 Model for Binding Calcium and Target. As a
model system, Ca2+-dependent S100-target interactions are
attractive, since S100s, in essence, have only one “functional”
EF-hand (EF2, Figure 2) per subunit, which for S100B does
notcooperatewiththeEF1orEF1
 /EF2
  oftheothersubunit
in Ca2+-binding [10, 23, 31, 78, 87, 109]. This is very
much unlike calmodulin (CaM) and troponin C (TnC),
which have several functional and highly cooperative EF-
hand Ca2+-binding domains [66]. Thus, a typical dimeric
S100-target interaction is Ca2+-dependent and involves at
least 11 possible states, 13 dissociation constants (K1–K13),
fourconformationalchanges(L1–L4),andthecorresponding
rate constants (k1–k17,k −1–k−17), per symmetric subunit
[109]( Figure 5). As for Ca2+-binding, the conformational
changes and the binding events for a single target are
also symmetric and occur independently of those on the
other subunit (i.e., without cooperativity), so only one
S100 subunit needs to be considered in the thermodynamic
scheme [10, 23, 31, 78, 87, 109]. At low [Ca2+]( Figure 5),
the predominant kinetic pathway for target binding to S100s
can be simpliﬁed to KI (k−1/k1,s t e p1 ) ,L 1 (k−14/k14), and
KX (k−10/k10, step 2) because an S100- or pseudo-EF-hand
motif (EF1) binds Ca2+ about an order of magnitude more
weakly than EF2 (KI   KII, i.e., KII ∼ 0.5mM) [109].
However, in addition to a two-step KI · L1 · KX pathway
for target binding, we will also consider three additional
equilibriums resulting from conformational exchange prior
to Ca2+ binding (KXIV), prior to target binding (KXV), as well
asfortheS100-targetboundstate(KXIV,Figure 5,Scheme 1).
In step 1 (Scheme 1), structural data provides support for
the “induced-ﬁt” aspect of Ca2+ binding to S100B (i.e., A
+C a 2+ ↔ [A − Ca2+]‡ ↔ B − Ca2+) since the apo-
S100B (state A) has a patch of negatively charged residues
comprising residues in the typical EF-hand (D65, E67, D69,
and E72) suﬃcient for a fast bimolecular interaction with
Ca2+ [23, 24]. Furthermore, no conformational exchange
(Rex)h a sy e tb e e no b s e r v e di n15N-relaxation rate NMR
studies of apo-S100B for any residues in helix 3 or in
either of the Ca2+-binding loops that subsequently undergo
structural transitions when Ca2+ is added [136]. However,
this needs to be examined more rigorously for apo-S100B
and for other apo-S100s using ZZ-exchange and relaxation
dispersion NMR methods (oﬀ-resonance R1ρ,r c C P M G ) .
Nonetheless, the lack of detectable Rex in the apo-state
currentlyprovidesanargumentagainsttheA ↔Bcon v ersion
(via KXIV)( Figure 5, Scheme 1, in green). In step 2, for target
binding to an S100 (i.e., B −MII+S↔ B −MII− S, via KX),
NMR data does exhibit Rex for both Ca2+-S100B and Ca2+-
S100A1 [59, 60, 77, 136, 137]; these preliminary data are
consistent with a model in which target binding selects a
competent conformation(s) from an ensemble of dynamic
states(viaKXV,i.e.,“selected-ﬁt”model[138]).Theselected-
ﬁt hypothesis is also supported by the loss of exchange
broadening upon binding of p53 and other targets to Ca2+-
S100B [77, 113]. Further, the rate of Ca2+ dissociation
(
Cakoﬀ) from EF2 decreases from 60/s to 7/s when p53
binds as measured by stopped-ﬂow methods [109]; similar
results were found when other targets, including an S100B
inhibitor (SBi1) bound to Ca2+-S100B (Cannon and Weber,
unpublished results). We now have X-ray crystal structures
of S100B-Ca2+ and S100B-Ca2+-TRTK12 that show Ca2+
coordination is indistinguishable in the two complexes [34],
whereas, elevated B-factors were observed for S100B-Ca2+
for residues in EF2 in the absence of bound target (Figure 4).
One interpretation of the elevated B-factors is that there is
conformational dynamics aﬀecting EF2 in the absence of
target, however, other explanations cannot be ruled out such
as the possibility that lattice contacts are diﬀerent in the two
structures giving rise to the changes in B-factors [34]. Thus,
it is important to further examine the dynamics of Ca2+-
S100s, including EF2, directly by NMR to determine whether
the decreased B-factors in EF2 (Figure 4)w e r ed u et oa
loss of conformational exchange as represented in Figure 5.
Additional evidence supporting Scheme 1 (Figure 5)i s
from stopped-ﬂow experiments with S100-Ca2+ and S100B-
Ca2+-target complexes [109]. Here, a fast kinetic-step at
the earliest time points in stopped-ﬂow traces has been
observed (i.e., biphasic, Cannon and Weber, unpublished
results), indicative of KXV. Also satisfying is that KXV in
Figure 5 provides a means for a single S100 protein to sample
conformational space (i.e., at BMII), as may be necessary
to bind more than one target protein, an observation
made for several S100 proteins [10]. Structurally similar
S100 proteins may also bind the same protein target (i.e.,
TRTK12), although koﬀ (i.e., k−10) in these cases usually
varies due to speciﬁc diﬀerences in the binding site that give
S100-target protein complexes unique conformations and
hence varying “lifetimes” inside the cell (i.e., diﬀerent
Cakoﬀ
values). These issues regarding speciﬁcity are important and
requirefurtherexamination. Itisalsonecessarytoremember
that one assumption in this model (Figure 5) is that binding
of Ca2+ to EF1 is not signiﬁcant. While this assumption is
valid based on existing KD values (and veriﬁed for S100B)
[87]), weak Ca2+ binding to this EF-hand (EF1) in other
S100s may slightly populate additional states, which together
with cooperative binding eﬀects observed in some cases
[15] could complicate interpretations with this simple model
(Figure 5).6 Cardiovascular Psychiatry and Neurology
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Figure 3: Metal ion and target binding properties of S100 proteins. (a) Binding studies with Mn2+ were completed since it is a good probe of
the high aﬃnity Ca2+ binding site on S100B (EF2) [113, 135]. Free Mn2+ was measured by electron paramagnetic resonance (EPR) in the
absence and presence of S100B (+/− target peptide TRTK12) [34] .I na l lf o u rt r a c e s ,t o t a l[ M n 2+] is identical (80μM) with the bottom trace
(4th trace) showing the signal for total [Mn2+]. TRTK12 alone (1mM) has no eﬀect on the EPR signal (3rd trace), whereas, the addition of
S100B (65μM) binds Mn2+ and reduces free [Mn2+] (2nd trace). The addition of the same amount of S100B (65μM) plus TRTK12 (1mM,
top trace) has the least free [Mn2+] and indicates that TRTK12 binding to S100B-Mn2+ enhances Mn2+ binding (compare traces 1 and 2).
A similar eﬀect was observed for SBi1 (unpublished) and for p53367−388 [109]. As for p53367−388 and SBi1, TRTK12 increased the aﬃnity of
S100B for Ca2+ in competition studies with Mn2+ and via stopped-ﬂow kinetic measurements of
Cakoﬀ as monitored in competition with
Tb3+. (b) Plot of the decrease in kobs as a function of [Ca2+]/[Tb3+]a su s e dt od e t e r m i n et h eo ﬀ rate of Ca2+ from the 2nd EF-hand (EF2,
Cakoﬀ). The kobs values at each [Ca2+]/[Tb3+] ratio were calculated from kinetic traces of stopped-ﬂow experiments where Tb3+ (syringe C)
is mixed with S100B at varying Ca2+ concentrations (syringe A) and [Tb3+] signal is monitored as a function of time (λex = 230nm, λem =
545nm). A
Cakoﬀ of 60 ± 8/sec was calculated from these experiments with S100B alone. When either TRTK12 or SBi1 is present, then the
calculated
Cakoﬀ value for S100B is reduced to 5 ± 3/sec similar to that found for p53367−388 [109]. These studies demonstrated that TRTK12,
p53367−388, or SBi1 increased the aﬃnity of S100B for Ca2+ at least in part by decreasing
Cakoﬀ. In (c), S100A1 was found to bind the full
length ryanodine receptor (RyR) at 100nM free calcium. Speciﬁcally, S100A1 competed full-length RyR1 away from agarose-linked CaM
beads as judged by a decreased RyR1 band in an anti-RyR Western blot. Free CaM, a positive control, also competed the RyR away from
CaM-linked beads [60, 67].
1.3. S100 Family Members Exhibit Overlapping but Distinct
Target Protein Binding Proﬁles. While structural, biochem-
ical, and biophysical approaches yield important structural
and mechanistic details, they cannot be used to screen simul-
taneously the interaction of multiple S100 family members
with an extensive array of full-length target proteins. There-
fore, we developed a quantitative assay that monitors the
interaction of ﬂuorophore labeled S100s with membrane-
immobilized target proteins that could be used to eﬃciently
identify/prioritize S100-target protein interactions and S100Cardiovascular Psychiatry and Neurology 7
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Figure 4: B-factors for X-ray structures of TRTK12-Ca2+-S100B (2.0 ˚ A) and Ca2+-S100B (1.5 ˚ A) from the PI’s laboratory. (a) B-factors for
backbone atoms for each subunit of Ca2+-S100B (blue, green) and for TRTK-Ca2+-S100B (red). (b) B-factors for sidechains with symbols as
in (a). (c) Also shown is a ribbon diagram of the TRTK12-Ca2+-S100B structure with residues colored red in EF2 (residues 61–72), which
display lower B-factors in the TRTK12-bound state (in panels (a) and (b)). These data are all published in Charpentier et al., 2010 [139].
domains for structural/mechanistic analyses. First, com-
mercially available Alexa-Fluor 488-conjugated calmodulin
(CaM-488) and two well-characterized calmodulin target
proteins, calmodulin-dependent kinase II (CaM kinase II)
and phosphorylase kinase, were used to determine if this
methodology would yield data representative of published
KDsa n dK As( Figure 6). The interaction of CaM-488 with
both target proteins was Ca2+ dependent. Immobilized CaM
kinase II bound 5.4pmoles CaM-488 in the presence of Ca2+
and 0.1pmoles CaM-488 in the absence of Ca2+. Similarly,
immobilized phosphorylase kinase bound 0.7pmoles CaM-
488 in the presence of Ca2+ and 0.3pmoles CaM-488 in the
absenceofCa2+.Furthermore,the8-folddiﬀerenceinbound
CaM-488 (5.4 versus 0.7pmoles) is in qualitative agreement
with the higher aﬃnity reported for CaM kinase II when
compared to phosphorylase kinase [140, 141]. These data
demonstrate the feasibility of using a membrane binding
assay and Alexa-Fluor conjugated Ca2+-receptor proteins to
monitor Ca2+ dependency of target protein interactions and
to qualitatively compare the binding interaction.
To verify that this methodology could also be used to
monitor S100-target protein interactions, the binding of
S100A1-488 to a previously characterized target protein,
glycogen phosphorylase a, was evaluated [73]. Consistent
with results of previous gel overlay and aﬃnity chromatog-
raphy experiments, S100A1-488 exhibited Ca2+-dependent
binding to immobilized glycogen phosphorylase a at all
points (Figure 7). Furthermore, S100A1-488 binding was
saturable with a Bmax of 30.0pmoles and EC50 for binding
value of 37.5pmoles. While this type of assay does not
provide a KD, the Bmax and EC50 can be used to compare
S100-target protein interactions. Nonetheless, full-binding
curves do not permit the simultaneous characterization of
multiple S100s interacting with numerous target proteins.
Therefore, two targets which exhibit diﬀerential interactions
with S100A1 and S100B were used to determine if a single
point assay like the one used in Figure 6 to characterize CaM
target protein interactions would accurately reﬂect S100
target protein interactions. The quantity of target protein
(50pmoles) and probe concentration (100nM S100A1-488
or S100B-488) were based on the EC50 (∼40pmoles) for
glycogen phosphorylase a in 100nM S100A1-488 (Figure 8).
S100A1-488 and S100B-488 exhibited Ca2+-dependent bind-
ing to phosphoglucomutase as well as glycogen phosphory-
lase, and the range of binding was similar to that observed
for CaM target proteins. Glycogen phosphorylase a and
b bound similar amounts of S100A1-488 (12–15pmoles)
and S100B-488 (15–20pmoles). In contrast, phosphoglu-
comutase bound 5-fold more S100B-488 (14pmoles) than
S100A1-488 (2pmoles). This diﬀerential binding was unde-
tectable in previous gel overlay and aﬃnity chromatography
experiments despite the diﬀerential eﬀects of S100A1 and
S100B on phospohglucomutase activity [142]. The insensi-
tivity/inability of the overlay and aﬃnity chromatography8 Cardiovascular Psychiatry and Neurology
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Figure 5: Models for Ca2+-binding and then target-binding to an S100 protein. ( T o p )Am o d e lf o rt h eC a 2+-dependent interaction of S100B
with target proteins involves 13 equilibrium constants (KI to KXIII), 11 states, and 4 conformational changes (LI–LIV)[ 109]. The most highly
populated states and the predominant pathway are colored red; this is due to weak Ca2+ binding in the pseudo-EF-hand (site I), which
greatly simpliﬁes this model (see Scheme 1). Speciﬁcally, the binding of Ca2+ to the pseudo- and typical EF-hand in each S100B subunit is
described by six states (A, AMI,A M II,A M IMII,B M I,a n dB M II), ﬁve equilibrium constants (KI = [A][M]/[AMI], KII = [A][M]/[AMII], KIII =
[AMI][M]/[AMI,II], KIV = [AMII][M]/[AMI,II], and KXI = [BMII][M]/[BMI,II], two conformational changes (LI:A M II ↔ BMII,L II:A M I,II ↔
BMI,II) with corresponding rate constants, respectively, where A = S100B prior to the 90
◦ reorientation of helix three of S100B, B = S100B
after 90
◦ reorientation of helix three, MI = aC a 2+ ion bound to EF-hand I (pseudo-EF-hand), MII = aC a 2+ ion bound to EF-hand II (typical
EF-hand), MI,II = Ca2+ ions bound to EF-hand I and EF-hand II. Upon the addition of p53 or another target (S), the model expands to 11
possible states, 13 dissociation constants, and four possible conformational changes. Whether additional equilibriums occur (KXIV,K XV,a n d
KXVI)i sc o n s i d e r e di nScheme 1. (Bottom) In a second model (Scheme 1), state A is deﬁned as the “closed” conformation observed in the
apo-state (Figure 2), and state B is after a 90
◦ reorientation of helix 3 termed the “open” conformation. In black, are states hypothesized to
be populated. [A-MII]‡ and [B-MII]‡ represent short-lived intermediates, and L1 is the Ca2+-dependent conformational change involving
helix 3 of S100B upon binding Ca2+ (Figure 2). Based on NMR relaxation rate data from the PI’s lab [136], KXIV highly favors state A. States
a r ea l s oc o n s i d e r e dv i aK XV and KXVI which result in B
∗ states that represent an ensemble of dynamic structures, of which, only a subset
fully coordinate Ca2+ as observed in X-ray structures [9]. It is hypothesized that KXV favors the B
∗MII state(s), whereas, KXVI favors B-MII-S,
explaining the apparent increase in Ca2+-binding aﬃnity using equilibrium binding measurements that monitor free [metal ion] (Figure 3).
Step 1 Step 2 LI
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B+M
KI KX
KXVI KXV KXIV
k14
k14
←→ ←→
↑↓ ↑↓ ↑↓ ↑↓
[A-MII]++
[B-MII]++
B-MII + S B-MII-S
B∗MII +S B ∗MII-S
←→
←→ ←→ ←→
Scheme 1
experiments to detect diﬀerential binding is most likely
attributable to the high levels of receptor and/or ligand
present. Altogether, these results demonstrate that a single
point ﬂuorometric assay can be used to quickly assess the
relative aﬃnity and Ca2+-dependency of S100-target protein
interactions.
Next, we compared the ability of diﬀerent S100 family
members (S100A1, S100A4, S100A5, and S100P) to interact
with four previously reported S100B targets, glycogen phos-
phorylase a, glycogen phosphorylase b, tau, and phospho-
glucomutase (Figure 8). As expected, all four target proteins
bound S100B-488 (10–35pmoles) in a Ca2+-dependent
manner. While none of the other family members exhibited
the same target protein binding proﬁle as S100B, there
did appear to be two distinct groups: one group (S100A1
and S100P) with proﬁles that were similar to and another
group (S100A4 and S1005) that clearly distinct from S100B.
Glycogen phosphorylase a and b bound similar levels of
S100A1-488/S100P-488. However, phosphoglucomutase did
not bind S100P-488 and 6-fold less S100A1-488 when
comparedtoS100B-488.Inaddition,taubound>10foldless
S100P-488 than S100B-488 and binding to S100A1-488 was
Ca2+ independent. In the case of S100A4 and S1005, binding
to all target proteins was below 10pmoles. Finally, labeled
S100A1, S100B, S100A4, and CaM (100nM) did not bind to
immobilized S100 family members (S100A1, S100B, S100A2,
S100A4, S100A5, S100A11, and S100A13), calmodulin, orCardiovascular Psychiatry and Neurology 9
the negative control α-lactalbumin (75pmoles) in the pres-
ence or absence of Ca2+ (data not shown). Collectively these
data demonstrate that while there is extensive overlap among
S100 family members with regard to the target proteins
that they interact with, each S100 interacts with a unique
compliment of target proteins. Nonetheless, there do appear
to be family member-speciﬁc target proteins. For example,
phospohglucomutase preferentially interacts with S100B.
Furthermore,therelativeaﬃnityandCa2+ dependencyofthe
interaction can vary among family members. For example,
tau is a target protein for multiple S100s including S100A1,
S100A4, S100A5, and S100P, but only the interaction of tau
with S100B is Ca2+-dependent.
1.4. The Linker Region Mediates Family Member-Speciﬁc
Binding. The linker region, the amino acid sequence that
links the two EF-hands, exhibits the greatest sequence
diversity among family members and has been postulated
to regulate family member-speciﬁc binding to target pro-
teins such as phosphoglucomutase. Consistent with this
hypothesis is the accessibility of this region to solvent
in both the apo- and Ca2+-bound states of all family
members for which 3D structures are available [10, 23,
57, 143]. To test this hypothesis, we checked the ability
of a recombinant S100B-A1-B chimeric protein to bind
to target proteins, in which the S100B linker region was
replacedwithcomparableaminoacidsequencefromS100A1
(Figure 8). This chimeric protein was readily puriﬁed using
similar procedures as used previously for S100B/S100A1,
and the mutations to the hinge region did not exhibit
any altered biochemical or biophysical properties tested.
As anticipated, the interaction of the ﬂuorophore-labeled
chimeric protein with the S100A1/S100B targets glycogen
phosphorylase a and b was indistinguishable from that of
S100A1-488andS100B-488,thatis,Ca2+-dependentbinding
in the 10–25pmole range. In contrast, phosphoglucomutase,
a target protein that preferentially interacts with S100B,
bound 2–4-fold less S100B-A1-B-488 when compared to
S100B-488. Interestingly, the presence of the S100A1 linker
region did not lower and/or reverse the Ca2+-dependent
interaction with tau. Additional experiments will be needed
to ascertain the linker region’s contribution to other family-
member speciﬁc target protein interactions as well as Ca2+-
independent target protein binding. Nonetheless, this is the
ﬁrst demonstration that the linker region does confer family-
speciﬁc binding for some Ca2+-dependent target proteins.
1.5. The Ca2+-Dependent Target Protein Binding Domain.
Carboxyl terminal aromatic residues (Phe88, Phe89, Trp90)
of S100A1 have been previously shown to regulate Ca2+-
dependent interaction of S100A1 with the TRTK peptide,
GFAP, and tubulin [72, 144, 145]. Analogous residues are
found in several other members including S100B, S100A4,
and S100A10 [78, 146–149]. To determine if these residues
are obligatory for Ca2+-dependent target protein interac-
tions, we examined the interaction of the S100A1 (F88/89A-
W90A)-488 with four additional S100A1 target proteins
(Figure 9).Asanticipated,mutantS100A1bindingtoallfour
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Figure 6: Characterization of CaM-488 target protein binding.
Equimolar concentrations of CaM kinase II (CKII) phosphorylase
kinase(PK)wereimmobilizedonaPVDFmembraneandincubated
with 100nM CaM-488 in the presence of Ca2+ or EDTA. Panel A
contains a representative dot blot image. The histograms in Panel
B represent the mean pmoles CaM-488 bound in the presence
(black bars) and absence (gray bars) of Ca2+ assayed in triplicate
in two independent experiments. Consistent with reported Kdsa n d
Kas, both targets exhibited Ca2+-dependent binding with the higher
aﬃnity target, CKII, binding more CaM-488 (7.0pmoles) when
compared to the lower aﬃnity target PK (0.8pmoles).
target proteins was decreased by ∼4-fold in the presence of
Ca2+. Interestingly, there was a 4-fold increase in mutant
S100A1 binding to tau in the absence of Ca2+. These results
conﬁrm that carboxy-terminal aromatic residues contribute
to the Ca2+-dependent interaction of S100s with protein
targets.However,itisnottheonlymechanismbecausenotall
family members that exhibit Ca2+-dependent target protein10 Cardiovascular Psychiatry and Neurology
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Figure 7: S100A1-488 binding curves for glycogen phosphorylase
a. Membranes containing varying concentrations of glycogen
phosphorylase were incubated in S100A1-488 in the presence (•)o r
absence ()o fC a 2+. A standard curve of ﬂuorescence intensity per
mg of S100-488 was used to determine the experimental amount of
labeled S100 per dot of target protein (n = 17).
interactions have hydrophobic residues in their C-terminal
extension [150].
2. Summary
In summary, S100 family members have a distinct role in
intracellular Ca2+ signaling. The complement of S100s and
S100 target proteins expressed in an individual cell allows
that cell to transduce a universal change in [Ca2+]i into
a unique biological response. Furthermore, their unique
metal binding properties and diverse lists of target proteins
provide mechanisms for conferring Ca2+/metal sensitivity to
cellular processes as well as integration and cross-talk among
these processes. Thus, delineating S100-regulated processes
in diﬀerent cell types, ascertaining the relationship between
intracellular and extracellular S100s, determining how S100-
regulated processes are altered by Ca2+ dysregulation in dis-
easestates,andidentifyingthatthemoleculareventsinvolved
are critical for understanding the function of this versatile
protein family. The combination of structural, biochemical,
molecular, cell biological, and in vivo techniques, which has
been successful to date, will ultimately identify “inhibitors”
ofS100functionthatcanbeusedtonormalizeCa2+ signaling
in diseased cells.
3.MaterialsandMethods
3.1. Bacterial Expression Vectors for Wild-Type S100 Family
Members. The pVex expression vector for human S100P
was a generous gift of Dr. George Makhatadze [151].
Bacterial expression vectors for S100A1 and S100B have been
previously described [152]. Plasmids encoding rat S100A4
(GenBank accession number AA997272) and S100A5 (Gen-
Bank accession number 1772854) were obtained through the
IMAGE consortium library (Research Genetics, Huntsville,
AL). The coding sequences were ampliﬁed using gene
speciﬁc primers containing synthetic Nde I and Hind
III sites at the 5  and 3  ends of the coding sequence,
respectively. The nucleotide sequences for the primers were
5 -TTCCATATGGCGAGACCCTTGGAGGAG-3  and 5 -
CCCAAGCTTCACTTCTTCCGGGGCTCC-3  (Lone Star
Labs,Houston,TX)forS100A4,5 -TTCCATATGGAGACT-
CCTCTTGAGAAG-3  (Invitrogen, Carlsbad, CA) and 5 -
CCCAAGCTTCACTTGTTGTCCTCTAAG-3  (Lone Star
Labs) for S100A5. Gene ampliﬁcation was performed using
an initial heat step (94
◦C, 5 minutes) followed by 30 cycles
consisting of 1 minute at 94
◦C, 1 minute at 60
◦C, and 2
minutes at 68
◦C, and a ﬁnal extension step of 7 minutes at
68
◦C. The resulting PCR products were subcloned into the
TA cloning vector PCR2.1 (Invitrogen, Carlsbad, CA). The
coding sequences were isolated from Nde I-Hind III digests
of plasmid DNA and subcloned into pET21a+ (Novagen, San
Diego, CA). The entire protein coding sequence was veriﬁed
by DNA sequence analysis.
3.2. Bacterial Expression Vectors for Mutant S100 Proteins.
The bacterial expression vector for the S100A1 triple point
mutant (F88/89A-W90A) has been described previously
[152]. A two-step PCR protocol followed by directional
subcloning was used to generate the expression vector for
the S100B-A1-B chimeric protein in which the amino acid
sequence for the linker region in S100B (HFLEEIKEQ) was
replaced with the S100A1 linker region (SFLDVQKDA). A
sense oligonucleotide containing the amino terminal S100B
sequence with an engineered Nde I restriction site (5 -
CGCCATATGTCTGAACTCGAGAAAGCTG, Invitrogen)
and a 3  antisense oligonucleotide encoding the amino
terminal half of the S100A1 linker region and an Xba
Is i t e( 5  -CCTCTAGAAAGCTGCTAAGTTC, Invitrogen)
were used to generate the 5  half of the chimeric protein.
The 3  half of the chimeric protein was generated using the
sametemplate,asenseoligonucleotideencodingthecarboxyl
terminal half of the S100A1 linker region and an Xba I
restriction enzyme site (5 -GCCATTTTCTAGACGTCC-
AGAAGGACGCGGAAGTTGTAGAC-3 ,I n t e g r a t e dD N A
Technologies, Coralville, IA) and an antisense oligonu-
cleotide encoding the amino terminus of S100B with an
engineered Hind III site (5 -CCCAAGCTTATTCATGTT-
CG, Intergrated DNA Technologies). The PCR program
consisted of 30 cycles (1 minute denaturing at 94
◦C, 1
minute of annealing at 55
◦C, and 3 minutes of extension
at 72
◦C). The resulting PCR products were ligated into the
TA cloning vector PCR2.1. Puriﬁed insert DNA encoding
the two halves of the chimeric protein was ligated together
and subcloned into pET21a+ using the 5  N d eIa n d3   Hind
III restriction sites. Restriction enzyme digest and sequence
analysisconﬁrmedthattheinsertsequenceencodedaprotein
with the appropriate amino acid sequence changes.
3.3. Expression/Puriﬁcation of Recombinant S100 Proteins.
Recombinant S100B, S100A1, and S100A1 triple point
mutant were puriﬁed as previously described [152]. Minor
modiﬁcations in this procedure were made to optimizeCardiovascular Psychiatry and Neurology 11
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Figure 8: Target protein binding proﬁles for S100 family members. Membranes containing glycogen phosphorylase (a) (Gpa), glycogen
phosphorylase (b) (Gpb), phosphoglucomutase (PGM), and tau (50pmoles) were incubated in 100nM Alexa Flour 488 labeled S100B
(blue bars), S100A1 (red bars), S100P (green bars), S100A4 (brown bars), and S100A5 (yellow bars) in the presence (darker bars) or absence
(lighter bars) of Ca2+. The histograms depict that the mean pmoles S100 bound ± the SEM and N’s denote no detectable binding. Asterisks
denote P ≤ .05 between the ±Ca2+ conditions.
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Figure 9: Interaction of wild-type and mutant S100s with target proteins. Membranes containing 50pmoles glycogen phosphorylase a (Gpa),
glycogen phosphorylase b (Gpb), phosphoglucomutase (PGM), and tau were incubated in 100nM S100B-488 (blue bars), S100A1-488
(red bars), chimeric S100B-A1-B-488 (purple bars), or S100A1(F88/89A-W90A)-488 (orange bars) in the presence (darker bars) or absence
(lighter bars) of Ca2+. The histograms depict that the mean pmoles S100 bound ± the SEM and N’s denote no detectable binding. The
asterisks denote P ≤ .05, and the N’s denote no detectable binding between the ±Ca2+ conditions.
puriﬁcation for S100A4, S100A5, S100P, and the S100B-A1-
B chimera. Unboiled bacterial lysates for S100A4, S100A5,
and S100P were fractionated by ammonium sulfate pre-
cipitation. Prior to phenyl-Sepharose chromatography, solid
ammonium sulfate was added up to 30% (w/v) to S100A4
[153] and up to 60% for S100P and S100A5. The unboiled
S100B-A1-B lysate and the S100A4, S100A5, and S100P
ammonium sulfate fractions were chromatographed on12 Cardiovascular Psychiatry and Neurology
phenyl-Sepharose resin equilibrated with 50mM Tris-Cl pH
7.4, 5mM CaCl2,a n d1m Mβ-mercaptoethanol. The resin
was washed with buﬀer containing high salt (50mM Tris-Cl
pH7.4,5mMCaCl2,1mMβ-mercaptoethanol,and500mM
NaCl). Protein was eluted in 50mM Tris-Cl, pH 7.4, 5mM
EDTA, and 1mM DTT. Fractions containing S100 protein
were identiﬁed by SDS-PAGE and pooled. The purity of
the protein preparations was assessed by SDS-PAGE. Protein
samples were considered to be >95% pure when only a single
band of ∼10,000kDa was visible on the Coomassie-blue
stained gel.
3.4. Alexa Fluor Conjugation. All wild-type and mutant
S100 proteins (5.0mg/ml in PBS) were labeled with the
photostableﬂuorophore,AlexaFluor488(MolecularProbes,
Eugene, OR), according to the manufacturer’s recommen-
dations. Prior to labeling, the pH was adjusted to ∼8.3
with 1M sodium bicarbonate and EDTA was added to a
ﬁnal concentration of 5.0mM. Alexa Fluor 488dye (1mg)
dissolved in DMSO was added to the protein sample. The
reaction was incubated at room temperature for one hour
in the dark with continuous stirring. Unconjugated dye was
hydrolyzed by incubation of the solution overnight in the
dark at 4◦C. After dilution with 1-2 volumes of water, the
pH of the solution was adjusted to 7.4 by the addition of 2M
Tris-Cl pH 7.4. Free dye was separated from protein conju-
gates by Ca2+-dependent phenyl-Sepharose chromatography
as described for protein puriﬁcation. Next, we determined if
this methodology could be used to quantify the binding of
S100 proteins to their various target proteins. Alexa Fluor
488 labeled S100A1, S100B, S100A4, S100A5, and S100P
exhibited physical characteristics that were indistinguishable
from unlabeled proteins including Ca2+-dependent binding
to phenyl-Sepharose (data not shown).
3.5. S100-Target Protein Binding Assay. Glycogen phospho-
rylase a, glycogen phosphorylase b, phosphoglucomutase
(PGM), and phosphorylase kinase were purchased from
Sigma Chemical Company (St. Louis, MO). Bovine brain
tau and calmodulin-dependent kinase II (CaM kinase II)
were generous gifts of Gloria Lee (University of Iowa) and
Tom Soderling (Vollum Institute, Portland, OR), respec-
tively. Varying concentrations of the target proteins were
immobilized on Immobilon-P PVDF membrane (Millipore)
using a 96-well dot-blot apparatus (BioRad, Hercules, CA)
per supplier’s instructions. After a 30-minute incubation,
wells were washed twice with three volumes of 20mM Tris-
Cl pH 7.4. The membrane was removed from the dot-
blot apparatus, cut into strips, and incubated overnight at
room temperature in 1μM Alexa Flour 488-labeled protein
in 50mM Tris-Cl, pH 7.4 with 200mM NaCl (buﬀer A)
containing either 5mM EDTA or 1mM CaCl2. The strips
were rinsed three times in buﬀer A containing 5mM
EDTA or 1mM CaCl2 and ﬂuorescence quantiﬁed on a
Fuji FLA-5000 Image Analysis System (Stamford, CT). A
standard curve of ﬂuorescence intensity versus pmoles of
PVDF-immobilized S100-488 (or Cam-488) was used to
determine the pmoles of labeled protein bound to that
concentration of target protein (n ≥ 2). Data points for each
target protein concentration were averaged together to yield
the mean pmoles of bound S100-488 ± SEM which was
calculated for each target protein. The student’s t-test was
used to determine the statistical signiﬁcance (P < .05) of any
measured diﬀerences between the means.
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